Ownership Capital B.V. Has $60.24 Million Position in Insulet Co. (NASDAQ:PODD)

Ownership Capital B.V. cut its position in Insulet Co. (NASDAQ:PODD) by 3.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 277,624 shares of the medical instruments supplier’s stock after selling 9,508 shares during the period. Insulet accounts for about 1.3% of Ownership Capital B.V.’s investment portfolio, making the stock its 21st biggest position. Ownership Capital B.V. owned 0.40% of Insulet worth $60,239,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Parkside Financial Bank & Trust boosted its position in Insulet by 251.0% in the third quarter. Parkside Financial Bank & Trust now owns 172 shares of the medical instruments supplier’s stock valued at $27,000 after buying an additional 123 shares in the last quarter. Allworth Financial LP boosted its position in Insulet by 104.5% in the third quarter. Allworth Financial LP now owns 180 shares of the medical instruments supplier’s stock valued at $29,000 after buying an additional 92 shares in the last quarter. Wolff Wiese Magana LLC boosted its position in Insulet by 2,680.0% in the fourth quarter. Wolff Wiese Magana LLC now owns 139 shares of the medical instruments supplier’s stock valued at $30,000 after buying an additional 134 shares in the last quarter. BluePath Capital Management LLC acquired a new position in Insulet in the third quarter valued at about $31,000. Finally, Lindbrook Capital LLC lifted its position in shares of Insulet by 64.1% during the fourth quarter. Lindbrook Capital LLC now owns 192 shares of the medical instruments supplier’s stock worth $42,000 after purchasing an additional 75 shares in the last quarter.

Insulet Trading Up 1.2 %

NASDAQ PODD traded up $2.02 during trading hours on Friday, hitting $166.19. The company’s stock had a trading volume of 636,152 shares, compared to its average volume of 670,432. Insulet Co. has a twelve month low of $125.82 and a twelve month high of $335.91. The company has a quick ratio of 2.62, a current ratio of 3.51 and a debt-to-equity ratio of 1.86. The firm has a market capitalization of $11.64 billion, a P/E ratio of 57.11, a PEG ratio of 2.96 and a beta of 0.98. The stock has a fifty day moving average of $171.51 and a 200 day moving average of $179.39.

Insulet (NASDAQ:PODD) last issued its earnings results on Thursday, February 22nd. The medical instruments supplier reported $1.40 EPS for the quarter, beating the consensus estimate of $0.67 by $0.73. Insulet had a net margin of 12.16% and a return on equity of 32.19%. The firm had revenue of $509.80 million during the quarter, compared to the consensus estimate of $461.26 million. During the same quarter in the prior year, the firm earned $0.55 earnings per share. The business’s quarterly revenue was up 37.9% on a year-over-year basis. Equities research analysts forecast that Insulet Co. will post 3.08 earnings per share for the current fiscal year.

Insider Buying and Selling at Insulet

In other Insulet news, Director Shacey Petrovic sold 11,609 shares of the company’s stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $162.92, for a total value of $1,891,338.28. Following the completion of the sale, the director now owns 2,567 shares of the company’s stock, valued at $418,215.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.90% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on PODD shares. Piper Sandler reduced their target price on shares of Insulet from $250.00 to $230.00 and set an “overweight” rating on the stock in a research report on Friday, February 23rd. JPMorgan Chase & Co. upped their target price on shares of Insulet from $190.00 to $225.00 and gave the stock an “overweight” rating in a research report on Friday, February 23rd. Barclays reduced their target price on shares of Insulet from $214.00 to $213.00 and set an “equal weight” rating on the stock in a research report on Monday, February 26th. Finally, Stifel Nicolaus upped their target price on shares of Insulet from $163.00 to $208.00 and gave the stock a “hold” rating in a research report on Monday, February 5th. Four research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $243.21.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.